1. Home
  2. MMS vs PTGX Comparison

MMS vs PTGX Comparison

Compare MMS & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Maximus Inc.

MMS

Maximus Inc.

HOLD

Current Price

$89.46

Market Cap

4.7B

ML Signal

HOLD

Logo Protagonist Therapeutics Inc.

PTGX

Protagonist Therapeutics Inc.

HOLD

Current Price

$83.77

Market Cap

5.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MMS
PTGX
Founded
1975
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.7B
5.4B
IPO Year
1997
2016

Fundamental Metrics

Financial Performance
Metric
MMS
PTGX
Price
$89.46
$83.77
Analyst Decision
Buy
Strong Buy
Analyst Count
1
9
Target Price
$90.00
$93.00
AVG Volume (30 Days)
642.9K
946.7K
Earning Date
02-05-2026
02-20-2026
Dividend Yield
1.34%
N/A
EPS Growth
10.42
N/A
EPS
5.51
0.72
Revenue
$5,431,276,000.00
$209,217,000.00
Revenue This Year
$1.71
N/A
Revenue Next Year
$4.98
$288.98
P/E Ratio
$16.30
$116.88
Revenue Growth
2.36
N/A
52 Week Low
$63.77
$33.70
52 Week High
$92.50
$96.54

Technical Indicators

Market Signals
Indicator
MMS
PTGX
Relative Strength Index (RSI) 62.11 39.17
Support Level $85.78 $84.11
Resistance Level $91.09 $89.61
Average True Range (ATR) 1.99 3.12
MACD 0.16 -0.93
Stochastic Oscillator 71.90 5.86

Price Performance

Historical Comparison
MMS
PTGX

About MMS Maximus Inc.

Maximus Inc designs, develops, and delivers programs enabling people to access vital government services. It translates health and human services public policy into operating models that achieve outcomes for governments at scale. The company covers a broad array of services, including the operation of large health insurance eligibility and enrollment programs; clinical services, including assessments, appeals, and independent medical reviews; and technology services. The company operates through the following segments: U.S. Federal Services, U.S. Services, and Outside the U.S. A majority of its revenue is derived from the U.S. Federal Services segment, which engages with various U.S. federal government agencies to deliver clinical services, maintenance services, and technology solutions.

About PTGX Protagonist Therapeutics Inc.

Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.

Share on Social Networks: